Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOD1 | Q9Y239 | 13/20 | 0.53 |
| ▸ | GNPAT | O15228 | 1/20 | 0.46 |
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | C3AR1 | Q16581 | 1/20 | 0.43 |
| ▸ | NPY1R | P25929 | 1/20 | 0.42 |
| ▸ | NPY2R | P49146 | 1/20 | 0.42 |
| ▸ | NPY4R | P50391 | 1/20 | 0.42 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.42 |
| ▸ | FNTA | P49354 | 1/20 | 0.42 |
| ▸ | FNTB | P49356 | 1/20 | 0.42 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1115964 | 1.00 | NOD1 (0.53) | NOD1GNPATSLC6A5EPHX2C3AR1 | |
| Hydrochloric Acid SCHEMBL3423146 | 0.99 | NOD1 (0.52) | NOD1GNPATSLC6A5EPHX2C3AR1 | |
| SCHEMBL29949573 | 0.93 | NOD1 (0.58) | NOD1GNPATSLC6A5EPHX2 | |
| Trifluoroacetic Acid SCHEMBL7445678 | 0.92 | NPY4R (0.49) | NOD1GNPATSLC6A5EPHX2C3AR1 | |
| SCHEMBL7135086 | 0.92 | NOD1 (0.64) | NOD1SLC6A5EPHX2 | |
| SCHEMBL11011526 | 0.92 | NOD1 (0.64) | NOD1SLC6A5EPHX2 | |
| SCHEMBL2343614 | 0.91 | NOD1 (0.66) | NOD1SLC6A5EPHX2 | |
| SCHEMBL359523 | 0.91 | NOD1 (0.66) | NOD1SLC6A5EPHX2 | |
| SCHEMBL2344383 | 0.91 | NOD1 (0.66) | NOD1SLC6A5EPHX2 | |
| SCHEMBL11102825 | 0.91 | NOD1 (0.66) | NOD1SLC6A5EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3272764-B1 | METHOD FOR AFFINITY CHROMATOGRAPHY | NOVARTIS AG (CH) | 2024-02-07 | — | — | EP | claimed |
| EP-2513134-B1 | WASH SOLUTION AND METHOD FOR AFFINITY CHROMATOGRAPHY | NOVARTIS AG (CH) | 2017-09-06 | — | — | EP | claimed |
| CN-102089319-B | Protein reforming method | AJINOMOTO KK | 2013-11-13 | — | — | CN | claimed |
| EP-2046393-A2 | CONTROLLED RELEASE OF PHENOLIC OPIOIDS | Pharmacofore, Inc. (US) | 2009-04-15 | — | — | EP | claimed |
| WO-2008101202-A1 | N-17-ALKYLATED PRODRUGS OF OPIOIDS | PHARMACOFORE, INC. (US) | 2008-08-21 | — | — | WO | claimed |
| WO-2007140272-A2 | CONTROLLED RELEASE OF PHENOLIC OPIOIDS | PHARMACOFORE, INC. (US) | 2007-12-06 | — | — | WO | claimed |
| CN-1680426-A | Purification method which prevents denaturation of an antibody | AJINOMOTO KK (JP) | 2005-10-12 | — | — | CN | claimed |
| CN-112955458-B | Method for producing refolded protein using flow microreactor and refolding device for protein | 味之素株式会社 | 2024-11-29 | — | — | CN | disclosed |
| EP-3272764-B1 | METHOD FOR AFFINITY CHROMATOGRAPHY | NOVARTIS AG (CH) | 2024-02-07 | — | — | EP | disclosed |
| WO-2023175064-A1 | METHODS FOR PURIFYING BISPECIFIC ANTIBODIES | ASTRAZENECA AB (SE) | 2023-09-21 | — | — | WO | disclosed |
| CN-112955458-A | Method for producing refolded protein using flow microreactor and apparatus for refolding protein | 味之素株式会社 | 2021-06-11 | — | — | CN | disclosed |
| CN-107365388-B | Method for preparing polymer protein | 味之素株式会社 | 2021-05-14 | — | — | CN | disclosed |
| CN-105517568-B | Method for preventing aggregation of viral components | 由卫生福利和体育大臣代表的荷兰王国 | 2020-07-07 | — | — | CN | disclosed |
| CN-102089319-A | Protein reforming method | AJINOMOTO KK | 2011-06-08 | — | — | CN | disclosed |
| US-20110077384-A1 | PROTEIN REFOLDING METHOD | AJINOMOTO CO., INC. (JP) | 2011-03-31 | — | — | US | disclosed |
| EP-2281827-A1 | PROTEIN REFORMING METHOD | Ajinomoto Co., Inc. (JP) | 2011-02-09 | — | — | EP | disclosed |
| CN-1680426-B | Purification method which prevents denaturation of an antibody | AJINOMOTO KK | 2010-05-26 | — | — | CN | disclosed |
| EP-2175019-A2 | Quasirandom structure and function guided synthesis methods | Nuevolution A/S (DK) | 2010-04-14 | — | — | EP | disclosed |
| US-20080193983-A1 | Quasirandom Structure and Function Guided Synthesis Methods | NUEVOLUTION A/S (DK) | 2008-08-14 | — | — | US | disclosed |
| CN-1680426-A | Purification method which prevents denaturation of an antibody | AJINOMOTO KK (JP) | 2005-10-12 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080193983-A1 | Quasirandom Structure and Function Guided Synthesis Methods | PARN, POLN, NCL | NOD1 210/4885GNPAT 2894/4885SLC6A5 2856/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.